StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Spyre Therapeutics's price to book ratio was 8.5× on Nov 11, 2026, against 4.0× a year earlier. Over the last 5 years it ranged from 0.2× to 11.6×, with a median of 3.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.5×+4.2
2025Dec 31, 20254.4×+0.7
2024Dec 31, 20243.7×+2.6
2023Jul 31, 20231.1×+0.7
2022Dec 30, 20220.4×−1.9
2021Dec 31, 20212.3×−0.3
2020Dec 31, 20202.6×−0.2
2019Dec 31, 20192.8×+0.2
2018Dec 31, 20182.6×+1.0
2017Dec 29, 20171.6×+0.7
2016Dec 30, 20160.9×–

More Spyre Therapeutics figures

See a number that looks wrong?